FDA Sends Warning Letters to Five Online Peptide Sellers Over Retatrutide and Tirzepatide Marketing

What Did the FDA Do to Online Peptide Sellers on 1 September 2026?

On 1 September 2026, the US Food and Drug Administration posted a cluster of warning letters — each dated 24 August 2026 — to five online peptide sellers: Peak Performance Peptides, Royal Peptides LLC, NuScience Peptides LLC, Peptide Partners LLC, and TXP Innovations LLC (doing business as Tex Peptides).[1] The agency's stated subject line is "Unapproved New Drugs/Misbranded," and trade press described it as an action against "unapproved GLP-1 websites."[2] Publishing several near-identical letters the same day points to a coordinated compliance sweep on marketing language, not a dispute unique to one seller, and follows similar FDA letters earlier in 2026 discussed below.[6]

Which Companies and Products Were Named?

Reporting on the broader sweep lists overlapping but not identical product citations across the five letters, including SS-31 and bacteriostatic water sold for reconstitution.[2] Two other letters in the batch — to Peptide Partners LLC (MARCS-CMS 735063) and TXP Innovations LLC dba Tex Peptides (MARCS-CMS 735067) — are separately indexed on the FDA's database, also dated 24 August 2026.[4][5]

Table for research reference only; individual letters cite overlapping but not identical product lists.

What Violation Is the FDA Alleging?

The core allegation is not about the chemical identity of the peptides themselves, but about how each website marketed them. Under the US Federal Food, Drug, and Cosmetic Act, a product becomes a "drug" in the legal sense when it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, or is intended to affect the structure or function of the body — regardless of how the seller privately labels it.[3] Once marketing language crosses that line, the product is treated as a "new drug" requiring FDA approval, and one that has not obtained it is both unapproved and, per the letters' subject line, misbranded.

None of the five letters, as reported, allege the named compounds are inherently illegal to sell in every context — tesamorelin is itself an FDA-approved medicine (Egrifta) when dispensed as a prescription drug under its own NDA. The issue is website-level marketing presenting these substances as ready-to-use treatments outside that approved pathway.

How Does This Fit the FDA's Broader 2026 Enforcement Pattern?

This is not an isolated action. The FDA issued comparable letters earlier in 2026 to Gram Peptides and Prime Sciences (both dated 31 March) and Wholesale Peptide (17 June), each citing similar unapproved-new-drug and misbranding concerns over semaglutide, tirzepatide, retatrutide, and cagrilintide.[6][7]

Read together, the pattern recurs roughly every one to two months in 2026: the FDA finds a batch of sellers whose copy has drifted from research-reagent framing into consumer treatment framing, and issues coordinated letters on the same statutory basis. It sits alongside separate 2026 FDA activity on the 503A/503B compounding bulks lists for some of the same compounds — a distinct track governing what licensed compounders may prepare, not what unlicensed websites may market to consumers.[8]

What Happens Next for the Five Companies?

FDA warning letters of this type typically give the recipient a limited window — commonly around 15 working days from the letter date — to describe corrective action taken or planned. Coverage of this batch places that window at roughly two weeks from the 24 August letter date, meaning a response would be due on or around 8 September 2026.[2] If a company responds adequately, the FDA typically closes the letter once cited marketing language is removed or corrected. If not, standard next steps include product seizure, injunction, or referral for criminal prosecution — though no such follow-on action against these five companies had been announced as of publication, and no public statement had confirmed whether any of them had responded.

Does This Affect UK Research-Reagent Supply or Velox Peptides?

No. This is a US action against five specific US-facing websites over how they marketed products — it is not a new restriction on any named compound and not a UK, Irish, or EU regulatory action. It has no bearing on the UK's Human Medicines Regulations 2012 or the legal status of research reagents supplied strictly for in vitro laboratory use; see our guide on whether research peptides are legal in the UK. It is, however, a useful case study in the marketing language a compliant research-reagent supplier must avoid, and pairs with the MHRA's own enforcement against illegal UK retatrutide manufacturing operations and Eli Lilly's civil suits over black-market retatrutide sales.

Every compound named in this article is supplied by Velox Peptides, where stocked, as a research reagent only. None is a medicine and none has been evaluated by the MHRA or FDA in this reagent form. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions